Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5981106 | 0.89 | PTK2 (0.46) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL1564458 | 0.83 | KMT2A (0.56) | MAPK10HTTALDH1A1MAPTNPC1 | |
| SCHEMBL10135173 | 0.80 | PTK2 (0.76) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL7056886 | 0.76 | PTK2 (0.70) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL1680689 | 0.76 | PTK2 (0.73) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL5478399 | 0.75 | PTK2 (0.63) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL14191967 | 0.74 | IKBKB (0.39) | HTTALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5099231 | 0.74 | IKBKB (0.36) | ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL11946878 | 0.74 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL13270043 | 0.74 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297128-B1 | INHIBITORS OF IKK- SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LD. (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-17 | — | — | US | disclosed |
| WO-2009130434-A1 | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| WO-2008053182-A1 | IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053185-A1 | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
| EP-1532133-A4 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | CALLAHAN JAMES F (US) | 2005-07-28 | — | — | US | disclosed |
| EP-1532133-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003104218-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | IKBKE, CSNK1A1, CSNK1E | PTK2 1455/4885MAPK8 692/4885MAPK10 691/4885 |
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | IKBKE, IKBKB, NFKBIA | PTK2 741/4885MAPK8 247/4885MAPK10 202/4885 |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | NFKBIA, IKBKG, IKBKE | PTK2 180/4885MAPK8 2048/4885MAPK10 792/4885 |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CSNK1E, PACSIN2, CHUK | PTK2 1182/4885MAPK8 2048/4885MAPK10 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.